3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
17
Glioblastoma
11
Melanoma
5
Brain Neoplasms
5
Rhabdoid Tumor
4
Osteosarcoma
4
Lymphoma
4
Glioma
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Recurrence
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Leukemia, Myeloid, Acute
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Wilms Tumor
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Neurofibromatosis 1
2
Neuroectodermal Tumors, Primitive
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Meningioma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Hepatoblastoma
2
Interventions
Cyclophosphamide
8
dinutuximab
7
Magnetic Resonance Spectroscopy
7
Topotecan
6
Doxorubicin
6
sargramostim
5
Vincristine
5
Stem Cell Transplantation
5
Radiation
5
Platinum
5
Melphalan
5
Isotretinoin
5
Colony-Stimulating Factors
5
Cisplatin
5
Biopsy
5
1,2-diaminocyclohexaneplatinum II citrate
5
Temozolomide
4
Specimen Handling
4
Irinotecan
4
Etoposide
4
Congresses as Topic
4
Carboplatin
4
Thiotepa
3
Busulfan
3
3-Iodobenzylguanidine
3
etoposide phosphate
2
Razoxane
2
Dexrazoxane
2
temsirolimus
1
lorlatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioneuroblastoma
×
fludarabine
×
CNS
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled